957774-27-5

Basic information

• Product Name: 5-bromo-2-chloro-4-hydroxybenzaldehyde
• Synonyms: 5-bromo-2-chloro-4-hydroxybenzaldehyde
• CAS NO: 957774-27-5
• Molecular Weight: 235.465
• Mol File: 957774-27-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-bromo-2-chloro-4-hydroxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-chloro-4-hydroxybenzaldehyde(957774-27-5)
• EPA Substance Registry System: 5-bromo-2-chloro-4-hydroxybenzaldehyde(957774-27-5)

Safety Data

• Hazardous Substances Data: 957774-27-5(Hazardous Substances Data)

Upstream product

• 3336-16-1 2-chloro-4-hydroxybenzonitrile 
• 1033723-49-7 5-bromo-2-chloro-4-methoxybenzaldehyde 
• 56962-11-9 2-chloro-4-hydroxybenzaldehyde 

Downstream Products

• 957774-28-6 4-(benzyloxy)-5-bromo-2-chlorobenzaldehyde 
• 1033723-50-0 5-bromo-2-chloro-4-(prop-2-en-1-yloxy)benzaldehyde 
• 957774-30-0 1-(benzyloxy)-2-bromo-5-chloro-4-[4-[2-(methoxymethoxy)ethyl]benzyl]benzene 
• 957774-29-7 [4-(benzyloxy)-5-bromo-2-chlorophenyl][4-[2-(methoxymethoxy)ethyl]phenyl]methanol 

Relevant articles and documents

5,5-DIFLUORO- AND 5-FLUORO-5-METHYL-C-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS

The present invention is directed to 5,5-difluoro- and 5-fluoro-5-methyl-C-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.

DUAL SGLT1/SGLT2 INHIBITORS

The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.

C-PHENYL GLYCITOL COMPOUND

Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein R1 and R2 are the same or different and represent a hydrogen atom, a hydroxyl group, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, R3 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, Y is a C1-6 alkylene group, -O-(CH2)n- (n is an integer of 1 to 4) or a C2-6 alkenylene group, provided that when Z is NHC(= NH)NH2 or -NHCON(RB)RC, n is not 1, Z is -CONHRA, -NHC(=NH)NH2 or -NHCON(RB)RC, Formula (A) or Formula (B).